title: DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
abstract: BACKGROUND
  The possibility of a dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase gene, DYRK2, predicting benefit from chemotherapy for patients with recurrent non-small cell lung cancer (NSCLC) was investigated.
  
  
  METHODS
  Forty patients with recurrent disease after surgery received several combinations of platinum-based chemotherapy. The chemotherapy effectiveness was evaluated according to RECIST (response evaluation criteria in solid tumors). Immunohistochemical (IHC) analysis was used to determine the expression of DYRK2.
  
  
  RESULTS
  Although the response rates between the two groups did not show statistical differences, the disease control rate of the DYRK2-positive group (15 out of 17, 88%) was significantly different from the DYRK2-negative group (8 out of 23, 35%, p=0.001). The median time to the progression (TTP) of disease was significantly different between the two groups (310 days in the positive group, 120 days in the negative, HR=2.12, 95% CI=[1.1-4.09], p=0.024). Multivariate analysis showed that negative DYRK2 expression was a strong predictor of disease progression (HR=3.01, 95% CI=[1.45-6.26], p=0.003).
  
  
  CONCLUSIONS
  Patients with high DYRK2 expression could be good candidates for chemotherapy.
authors: Department of Surgery II, Faculty of Medicine, Oita University, Yufu, Oita 879-5593, Japan. yamashi1@med.oita-u.ac.jp
authors: Shin-ichi
authors: S
authors: Yamashita
authors: Masao
authors: M
authors: Chujo
authors: Toshihiko
authors: T
authors: Moroga
authors: Kentaro
authors: K
authors: Anami
authors: Keita
authors: K
authors: Tokuishi
authors: Michiyo
authors: M
authors: Miyawaki
authors: Yozo
authors: Y
authors: Kawano
authors: Shinsuke
authors: S
authors: Takeno
authors: Satoshi
authors: S
authors: Yamamoto
authors: Katsunobu
authors: K
authors: Kawahara
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000097:blood* / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000097:blood* / Q000235:genetics; D000097603:Dyrk Kinases
chemical_list: D014408:Biomarkers, Tumor; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D000097603:Dyrk Kinases